Breaking News

GSK Licenses RA Drug from ChemoCentryx

Pays $25 million for worldwide development and commercialization license

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline has exercised its option to obtain an exclusive worldwide license to further develop and commercialize ChemoCentryx’s investigational drug CCX354 for the treatment of rheumatoid arthritis (RA). ChemoCentryx recently reported positive results from a Phase II trial investigating the safety, tolerability, clinical and biological activity of CCX354 in patients with RA. ChemoCentryx will receive an option exercise fee of $25 million and will be eligible for further regulatory and sal...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters